AMLN—Judging from my reading today, there is a host of analysts, media writers, commentators and other assorted stone-throwers with little or no knowledge of what HbA1c level really means to either a normal person, or a T1 diabetic or a T2 diabetic.
For readers of this board in particular, I would respectfully disagree; I think most readers here do understand what HbA1c is all about.
If I had the authority, I would fire whoever wrote or approved today's PR from AMLN/LLY.
What would you have them say??
In any non-inferiority study, there’s a prespecified delta that governs how much worse a drug can be relative to the comparator while still being considered statistically non-inferior. Bydureon failed to meet this threshold in the study in question.